In BCIRG-006, HER2 positive breast cancer was treated with anthracycline, taxane, plus trastuzumab showed equivalent prognoses, irrespective of TOP2A status (5-year DFS; TOP2A amplified vs. normal/deleted, 85% vs. 83%) [32]. This evidence concerns the gene TOP2A and breast carcinoma.